score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable	Guideline	Guideline		Copy Number	AR	Amplification				0.0	0.0		Putatively Actionable	Abiraterone	Hormone therapy	Androgen receptor activation may predict sensitivity to second generation androgen deprivation or direct androgen inhibitors.	National Comprehensive Cancer Network. Prostate Cancer NCCN Evidence Blocks (Version 3.2016). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/prostate_blocks.pdf	Putatively Actionable	Abiraterone	Hormone therapy	Androgen receptor activation is a potential mechanism of recurrence of prostate cancer during androgen deprivation therapy.	National Comprehensive Cancer Network. Prostate Cancer NCCN Evidence Blocks (Version 3.2016). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/prostate_blocks.pdf						0				AR Amplification		PROS01448-6115251	PROS01448-6115251-Tumor-SM-67ES6	
Investigate Actionability - High		Clinical evidence	Clinical evidence	Somatic Variant	TP53	Missense	p.I255F	0.6032	63.0	0.0	0.0								Investigate Actionability - Low	Lenalidomide	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability - High	0.0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0	33.0	0.7273	1.0	TP53 p.I255F (Missense)		PROS01448-6115251	PROS01448-6115251-Tumor-SM-67ES6	PROS01448-6115251-Normal-SM-67ET4
Investigate Actionability - High			Clinical evidence	Copy Number	MYC	Amplification				0.0	0.0														Investigate Actionability - High	0.0	Poor prognosis (< 15%) was observed for patients with amplified MYC with Medulloblastoma.	Ryan SL, Schwalbe EC, Cole M, et al. MYC family amplification and clinical risk-factors interact to predict an extremely poor prognosis in childhood medulloblastoma. Acta Neuropathol. 2012;123(4):501-13.	https://doi.org/10.1007/s00401-011-0923-y	0				MYC Amplification		PROS01448-6115251	PROS01448-6115251-Tumor-SM-67ES6	
Biologically Relevant				Copy Number	ATM	Deletion				0.0	0.0																			0				ATM Deletion		PROS01448-6115251	PROS01448-6115251-Tumor-SM-67ES6	
Biologically Relevant				Copy Number	KRAS	Deletion				0.0	0.0																			0				KRAS Deletion		PROS01448-6115251	PROS01448-6115251-Tumor-SM-67ES6	
Biologically Relevant				Microsatellite Stability	Supporting variants		PRDM2 p.703_704insP (Insertion)																							0				Supporting variants: PRDM2 p.703_704insP (Insertion)		PROS01448-6115251		
Biologically Relevant				Mutational Signature	COSMIC Signature 1		0.411																							0				COSMIC Signature 1 (41%)		PROS01448-6115251		
Biologically Relevant				Mutational Signature	COSMIC Signature 6		0.261																							0				COSMIC Signature 6 (26%)		PROS01448-6115251		
